Pharma Buyl-Louise SRL
Pharma Buyl-Louise reported total assets of 380,658 € at the end of the 2025 financial year (annual accounts filed with the NBB on 02 Jun 2026).
The score of Pharma Buyl-Louise shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +61 % Total assets +9 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Pharma Buyl-Louise's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 02 Jun 2026
- Year ended 31 Dec 2024filed on 12 Aug 2025
- Year ended 31 Dec 2023filed on 02 Jul 2024
- Year ended 31 Dec 2022filed on 28 Jun 2023
- Year ended 31 Dec 2021filed on 30 May 2022
Pharma Buyl-Louise's financial analysis
- Solvency40.0%sector median: 37.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Pharma Buyl-Louise
Pharma Buyl-Louise's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0764.926.261
- VAT number
- BE0764926261
- Peppol
- Registered · 0208:0764926261 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 11 Mar 2021
- Registered office
- 1050 Ixelles
- Latest accounts
- 2025 · filed on 02 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Pharma Buyl-Louise (SRL) has been based in Ixelles since 2021, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 72,981 € and equity of 152,271 €; its revenue is not published. Its solvency stands at 40.0%, above the median of its sector (37.6%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Pharma Buyl-Louise
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie Schubert Retail sale of pharmaceutical products Uccle · balance sheet 370,234 €
- Apotheek Hilde Lippens Retail sale of pharmaceutical products Knokke-Heist · balance sheet 378,020 €
- Van de Keere Retail sale of pharmaceutical products Zottegem · balance sheet 366,717 €
- Natexis Retail sale of pharmaceutical products Auderghem · balance sheet 404,337 €
- Dewez Invest Retail sale of pharmaceutical products Visé · balance sheet 419,029 €
- Vereenooghe SEW Retail sale of pharmaceutical products Ledegem · balance sheet 426,561 €
- Yapharm Retail sale of pharmaceutical products Uccle · balance sheet 436,227 €
- Farmacerèye Retail sale of pharmaceutical products Liège · balance sheet 326,499 €
Frequently asked questions about Pharma Buyl-Louise
What is the revenue of Pharma Buyl-Louise?
Pharma Buyl-Louise files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Pharma Buyl-Louise?
In Belgium, the VAT number is the company number prefixed with BE: BE0764926261 for Pharma Buyl-Louise, if the company is VAT-registered. Its company number (CBE) is 0764.926.261.
Where is the registered office of Pharma Buyl-Louise?
According to the CBE register, the registered office of Pharma Buyl-Louise is in 1050 Ixelles.
What is the equity of Pharma Buyl-Louise?
At the close of the 2025 financial year, the equity of Pharma Buyl-Louise amounts to 152,271 €, a solvency of 40.0% of total assets.
Who manages Pharma Buyl-Louise?
The register lists 1 active mandates at Pharma Buyl-Louise. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Pharma Buyl-Louise
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →